Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Biosimilars Switching Debate Escalates After Remicade and Remsima Match In Landmark Study

Executive Summary

Biosimilar drug makers say that the NOR-SWITCH study on switching from Johnson & Johnson’s infliximab to the Celltrion product supports the concept of biosimilarity and proves that they are subject to the same regulatory standards as originators. Originators, meanwhile, want more evidence that switching works.

Advertisement

Related Content

Canada Attempts Biosimilar Balancing Act
Biosimilars Boost In Europe: 2017 Kicks Off With Three Approvals And Backing From ESMO
Italy To Relax Biosimilar Switching Rules In Cost-Savings Effort
ACR 2016 Roundup: Remicade Copy Not So Similar; Mixed Sirukumab Results; Corbus’s Resunab Surge
NOR-SWITCH Results ‘Concerning’ In Crohn’s Disease, Says Janssen
Biosimilar Interchangeability: NOR-SWITCH-Type Study Not Enough For US FDA
J&J Maintains Strategy For Biosimilar Remicade As Inflectra Nears

Topics

Advertisement
UsernamePublicRestriction

Register